Lawrence Eichenfield Net Worth

Lawrence Eichenfield biography

Dr. Lawrence Eichenfield M.D. has been appointed as Director of the Company effective 8/1/2020. He has been the chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego since 1991, as well as vice chair of the Department of Dermatology and a professor of dermatology and pediatrics at UC San Diego School of Medicine since 2009. He served as President of the Society for Pediatric Dermatology in 2002-3, on the board of the American Academy of Dermatology from 2005 to 2009, and served as chair for the 69th Annual Meeting of the American Academy of Dermatology. He is a co-Founder and former Chair of the Pediatric Dermatology Research Alliance (PeDRA), a collaborative research network, and a founding board member and past-president of the American Acne and Rosacea Society. He served as Editor-in-Chief of Pediatric Dermatology for 12 years and serves on the editorial boards of multiple journals and periodicals. Dr. Eichenfield earned his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and chief resident at Children’s Hospital of Philadelphia, and completed dermatology training at the hospital of the University of Pennsylvania. He is board certified in pediatrics, dermatology and pediatric dermatology. He has been honored as a member of the Alpha Omega Alpha Honor Society during medical school, and as a recipient of multiple clinical excellence and teaching awards from the Children’s Hospital of Philadelphia, UC San Diego Pediatrics, UC San Diego Dermatology and Rady Children’s Hospital-San Diego.

How old is Lawrence Eichenfield?

Lawrence Eichenfield is 62, he's been the Director of Verrica Pharmaceuticals Inc since 2020. There are no older and 14 younger executives at Verrica Pharmaceuticals Inc.

What's Lawrence Eichenfield's mailing address?

Lawrence's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER, PA, 19380.

Insiders trading at Verrica Pharmaceuticals Inc

Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning und John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.

What does Verrica Pharmaceuticals Inc do?

verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.

Verrica Pharmaceuticals Inc executives and stock owners

Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Ted White,
  President, Chief Executive Officer, Director
• Brian Davis,
  Chief Financial Officer
• Joe Bonaccorso,
  Chief Commercial Officer
• Ted White,
  Pres, CEO & Director
• Dr. Gary Goldenberg M.D.,
  Chief Medical Officer
• Mark Prygocki,
  Independent Director
• Gary Goldenberg,
  Chief Medical Officer
• Craig Ballaron,
  Independent Director
• Sean Stalfort,
  Director
• Diem Nguyen,
  Director
• Lawrence Eichenfield,
  Director
• Bradley Catalone,
  Head of Drug Development
• Patrick Burnett,
  Chief Medical Officer
• Christopher Hayes,
  General Counsel, Corporate Secretary, Chief Legal Officer
• Paul Manning,
  Chairman of the Board
• Dr. Bradley J. Catalone MBA, Ph.D.,
  Head of Drug Devel.
• Eugene Scavola,
  Exec. VP of Technical Operations
• Joe Bonaccorso,
  Chief Commercial Officer
• Christopher G. Hayes,
  Chief Legal Officer, Sec. & Gen. Counsel
• P. Terence Kohler,
  Chief Financial Officer
• Matt Davidson,
  10% owner
• John A Iii Stalfort,
  Director
• Glenn A Oclassen,
  Director
• Advisors Llcperceptive Life...,
  
• Linda Palczuk,
  Chief Operating Officer
• Chris Degnan,
  Chief Financial Officer
• Terry Kohler,
  CHIEF FINANCIAL OFFICER